A cosmetic ingredient, not regulated or approved as a drug. This page is educational information only, not medical advice.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Dipeptide-2

Cosmetic ingredient

Cosmetic signal peptide

Also known as: Eyeliss, Val-trp, L-Valyl-L-tryptophan, L-Tryptophan, L-valyl-, valyltryptophan, N-Valyltryptophan, N-L-Valyl-L-tryptophan, DIPEPTIDE VW

Evidence score

23/ 100

Thin evidence

Very thin human evidence

Regulatory standing. Cosmetic ingredient, not regulated as a drug
Animal / preclinical only. Evidence is largely animal or in-vitro
No registered human trials. Nothing registered on ClinicalTrials.gov
1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Dipeptide-2 is a short two amino acid peptide (valine and tryptophan) used in skincare, often as part of the commercial ingredient blend sold as Eyeliss. It is marketed for the under-eye area and is thought to support lymphatic drainage and reduce fluid buildup, though this mechanism comes mainly from lab and manufacturer work.

What the evidence shows

Automatic summaryAnimal / preclinical

There are no registered human clinical trials, and support for reduced eye puffiness comes largely from manufacturer-sponsored cosmetic testing rather than independent controlled studies. It is regulated as a cosmetic ingredient, is not FDA-approved for any medical use, and its effects in humans remain unestablished.

Key facts

Molecular formula

C16H21N3O3

Molecular weight

303.36 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

0registered studies

Nonemost advanced phase

0completed (sample)

0recruiting (sample)

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

20papers referencing Dipeptide-2

Ligands for the tyrosine kinase p56lck SH2 domain: discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements.

J Med Chem1999

Differential sleep-promoting effects of five sleep substances nocturnally infused in unrestrained rats.

Proc Natl Acad Sci U S A1984

Catalytic asymmetric Simmons-Smith cyclopropanation of silyl enol ethers. Efficient synthesis of optically active cyclopropanol derivatives.

Org Lett2006

Self-Assembly Dipeptide Hydrogel: The Structures and Properties.

Front Chem2021

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.